Search Results

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company and Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization --Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like

November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals , Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has successfully completed

July 2022 "Not even a PIPE financing could save X4 Pharmaceuticals from enacting layoffs and trimming

June 2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals

with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery "Apr.19.2022 Ono Pharmaceutical

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa

monoclonalantibodies #drugdiscovery #biotechnology #research #ionchannels #biologics #biotech #pharma #pharmaindustry #pharmaceuticals

Therapeutics To Release Half-Year 2023 Financial Results And Host Conference Call On August 10, 2023 X4 Pharmaceuticals adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results And Provides Corporate Update X4 Pharmaceuticals Announces

- 4, 2024 | Chemotactic Cytokines GPCR Jobs NEW Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals NEW Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Jobs NEW Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

Apprentice Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

research in biomedical sciences with the mechanistic understanding of one of the biggest classes of pharmaceutical

recently had the pleasure of speaking with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

"Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical

Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical

Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical

GPCR Jobs Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals In vivo Antibody Discovery Research

Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals

"Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical

Multi-Product Pipeline Toward Clinical Studies Confo Therapeutics Appoints Dieter Weinand, Former CEO Of Bayer Pharmaceuticals Wainwright 25th Annual Global Investment Conference X4 Pharmaceuticals to Participate in the Morgan Stanley

Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 Crinetics Pharmaceuticals Cushing’s Syndrome (ADCS) Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals

expansion as the leading GPCR immuno-oncology company Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer Rhythm Pharmaceuticals and LG Chem Life Sciences

Tagging GPCRs expressed in cellular compartments such as the nucleus or endosomes presents several pharmaceutical Overall, the pharmaceutical challenges associated with tagging GPCRs expressed in cellular compartments Pharmaceuticals (Basel, Switzerland), 14(5), 439. https://doi.org/10.3390/ph14050439 Chen, K.

Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical